Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 6

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 6
---
 be broadly
deployed across high-burden diseases.

Corporate Information

We were incorporated as AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in October 2017 and to MiNK
Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is 212-994-8250.
Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus.

S-2

THE OFFERING The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not contain all the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled “Description of Common Stock” in the accompanying prospectus.

| Common stock offered by us | Shares of common stock having an aggregate offering price of up to $50,000,000. |

| Common stock outstanding after this offering | Up to 5,196,820 shares, assuming sales of 1,231,223 shares of common stock in this offering at an offering price of $40.61 per share, which was the last reported price of our shares of common stock on the Nasdaq Capital Market on 
 July 14, 2025. The actual number of shares issued will vary depending on how many shares we choose to sell under this offering.                                                                                                       |

| Plan of Distribution | “At the market offering” that may be made from time to time for our common stock in the United States through the Sales Agent. See the section entitled “Plan of Distribution” below. |

| Use of proceeds | We intend to use the net proceeds from this offering, if any, for working capital and other general corporate purposes which may include, without limitation, research and development expenditures, preclinical and clinical development and 
 commercialization of our product candidates, the acquisition or in-licensing of products or product candidates, business or technologies, collaborations, working capital and capital expenditures. We have not                               
 determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds.                                                                    |

| Risk factors | Your investment in our common stock involves substantial risks. You should consider the “Risk Factors